key: cord-0905719-owryhuxa
authors: Reik, Rita; Gammon, Richard R.; Carol, Nancy; Smith, Judith; Grable, Martin; Forbes, Susan; Wu, Yanyun; Reed, Lance; Rogers, Michael; Prichard, Alicia; Paul, Scott; Scholl, George
title: Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience
date: 2021-03-01
journal: J Clin Apher
DOI: 10.1002/jca.21889
sha: 1a42c23f492a09f00672be4ae1216a1fe0e7f128
doc_id: 905719
cord_uid: owryhuxa

BACKGROUND: During the pandemic in the spring of 2020 with no vaccine or treatment for SARS‐CoV‐2 and its associated disease, COVID‐19, convalescent plasma from recovered COVID‐19 (CCP) patients offered a potential therapy. In March 2020, the United States (U.S.) Food and Drug Administration (FDA) authorized CCP under emergency Investigational New Drug (eIND) exemption and an IRB‐approved Expanded Access Program (EAP) to treat severe COVID‐19. Hospital demand grew rapidly in the Southeastern U.S., resulting in backlogs of CCP orders. We describe a large U.S. blood center's (BC) rapid implementation of a CCP program in response to community needs. STUDY DESIGN AND METHODS: From April 2 to May 17, 2020, CCP was collected by whole blood or apheresis. Initial manual approaches to donor intake, collection, and distribution were rapidly replaced with automated processes. All CCP donors and products underwent FDA‐required screening and testing. RESULTS: A total of 619 CCP donors (299 females, 320 males) presented for CCP donation (161 [25.7%] whole blood, 466 [74.3%] plasmapheresis) resulting in 1219 CCP units. Production of CCP increased as processes were automated and streamlined, from a mean of 11 donors collected/day for the first month to a mean of 25 donors collected/day in the subsequent 2 weeks. Backlogged orders were cleared, and inventory began to accumulate 4 weeks after project initiation. CONCLUSION: The BC was able to implement an effective de novo CCP collection program within 6 weeks in response to a community need in a global pandemic. Documentation of the experience may inform preparedness for future pandemics.

The novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, as an unusual outbreak of pneumonia in Wuhan, the capital of Hubei Province, China. The associated disease was named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Following the first report to WHO on December 31, 2019, SARS-CoV-2 began spreading rapidly internationally. On January 30, 2020, WHO declared the SARS-CoV-2/ COVID-19 outbreak to be a public health emergency of international concern and on March 11, 2020, deemed it a global pandemic. 1 On January 20, 2020, the first confirmed case of COVID-19 in the U.S. was identified in Washington State. 2 As of July 5, 2020, the case fatality rate for COVID-19 was 4.6%. 3, 4 On January 5, 2020, as a result of blood center (BC) hemovigilance monitoring, Senior Leadership at the BC was alerted to the potential significance of SARS-CoV-2 via an internal email communication referencing an article of interest about a virus outbreak in Wuhan, China affecting 44 people. 5 By early March, the pandemic started to significantly impact the BC's service area. Shelter-in-place orders and social distancing measures began to affect blood collections, raising concerns about the adequacy of the regional blood supply. However, following the cancelation of elective surgeries at area hospitals to make beds available for the large influx of COVID-19 patients, the demand for traditional blood products dropped~50%.

COVID-19 symptoms range from mild to life-threatening, requiring intensive care and mechanical ventilation with supplemental oxygen. 6 This life-threatening aspect of the disease has resulted in over-burdened healthcare systems both globally and in the U.S. 7 Treatment is largely supportive. Favorable experience with convalescent plasma in other viral infections including coronavirus (SARS-CoV-1), Ebola, middle eastern respiratory syndrome (MERS), and avian influenza led to interest in using convalescent plasma from recovered COVID-19 (CCP) as a treatment for COVID-19. Small early studies from China suggested clinical improvement with the use of CCP in COVID-19. 8, 9 In light of this, on March 24, 2020, the U.S. Food and Drug Administration (FDA) authorized the use of CCP for treatment of serious or immediately life-threatening COVID-19 through the following pathways: clinical trials, single patient emergency investigational new drug (eIND) or under an expanded access protocol (EAP) through the National Expanded Access Treatment Protocol. 10, 11 We herein describe a large U.S. BC's experience in implementing a CCP program. In 2019, the BC had~3000 employees, collected  718 349 units of whole blood, 136 465 apheresis products,  and distributed 554 units of whole blood, 799 321 red  blood cell (RBC) units, 153 566 platelet units, 151 138  plasma units and 158 425 individual cryoprecipitate AHF units in five states to over 400 hospitals. All required transfusion-transmitted infectious disease (RTTID), red blood cell antibodies, and HLA antibody testing was performed by an outside facility. On March 24, 2020, the BC launched a CCP implementation project with goals of meeting the need for CCP and building a robust inventory of frozen and liquid CCP to be made available for rapid fulfillment of orders. Recognizing the uniqueness and urgency of the situation, BC Senior Leadership committed to the hands-on running of the project throughout the startup and additionally engaged an expert consultant who had experience with the COVID-19 outbreak in China to assist in the CCP program design and development. 12 The BC business continuity plan (BCP), that was prepared previously and reviewed annually to address disruptions in operations, had been previously activated in the context of the global pandemic. The Project Management Office (PMO) was enlisted to support the design and management of the CCP project. Institutional Review Board approval was obtained (Advarra-Pro00038077) and written informed consent was obtained from all donors who participated in this study. Existing BC staff were cross-trained and redeployed into various aspects of the project eliminating the need to hire additional staff.

The urgent clinical need for CCP necessitated a two-phase approach to the implementation of CCP production. Phase 1 (March 24-April 27, 2020) involved primarily manual processes and was designed to get collections and distribution of CCP implemented quickly. During phase 2 (April 28-May 17, 2020), progressive process streamlining and automation enhanced CCP donor recruitment, intake, scheduling, and distribution to boost the volume of operations and inventory. (Figure 1 ). developed and by March 30, 2020, an 888-HelpLine was launched for intake and manual tracking of potential CCP donors. A coordinated media and public relations campaign was enacted in conjunction with an integrated social media appeal to create awareness for the urgent need for people who recovered from COVID-19 to register with the BC to be a CCP donor. The Florida Department of Health (FDOH), the Florida Governor's office, and the Florida Medical Association (FMA) assisted in identifying CCP donors. On April 2, 2020, the first unit of CCP was collected from whole blood and transfused as liquid plasma the next day.

Donors presenting during phase 1 consisted primarily of recovered COVID-19 patients identified by physicians or family members, who volunteered as directed donors for those with life-threatening COVID-19. Eligible patients had to be identified to the BC by their physician by means of an eIND or EAP patient number. During the first week of the project, most hospitals and physicians ordered CCP using the eIND pathway and obtained F I G U R E 1 Overview of CCP program development approval directly through the FDA's Office of Emergency Operations. 11 Additionally, CCP orders were also using the EAP pathway through the MAYO Clinic protocol. BC staff were available continuously throughout this period to field questions from donors and physicians, receive orders from hospitals, and communicate with the FDA, F I G U R E 2 BC CCP website landing page F I G U R E 3 BC CCP website physician landing page FDOH, and FMA. CCP donors were recruited according to FDA criteria ( Figure 4 ). 10 Potential donors and/or their referring physicians were directed to the BC CCP recruitment website, 888-HelpLine, or encrypted email where they completed a written informed consent, a health history questionnaire form ( Figure 5 ), and uploaded their SARS-CoV-2 laboratory reports. Donor intake information was reviewed by BC staff and forwarded to the BC Medical Directors for approval. Copies of laboratory testing were verified, and laboratory test sites and tests used were checked for acceptability using the FDA website as a reference. 13 Following successful intake, pre-screening of the full donor history questionnaire was administered by telephone. The prescreen was intended to optimize blood center collection capacity and staffing, and compliance with "shelter-in-place" orders by increasing the probability that those donors who presented would be qualified for CCP donation.

Donors passing initial screening steps were scheduled for the earliest available appointment. Collections took place on six dedicated mobiles (designed to have 4-6 donor beds) in a setting that observed all social distancing precautions and personal protective equipment (PPE) recommendations made by the Centers for Disease Control and Prevention (CDC) regarding masks, gloves, surface disinfection, and a minimum of 6 ft. (2 m) of distance between persons. Each mobile was able to accommodate 12 donors per day and only one donor was collected during one appointment time. Products were collected as whole blood or plasmapheresis depending on donor preference and staff assessment. As staff experience was gained with plasmapheresis collections, the BC moved to collect almost all donations by this method.

Whole blood plasma collection was performed using Haemonetics bags (Haemonetics, Braintree, Mass.). Apheresis plasma collection was performed using Fresenius Kabi Alyx equipment with Fresenius Kabi 4R5730 bags (Fresenius Kabi USA, Lake Zurich, Illinois), and Terumo BCT TRIMA equipment with TRIMA set plasma/RBC kit, type 80 500 (Terumo BCT, Lakewood, Colorado) instrumentation following the manufacturer's recommendations. At the time of collection, units were tagged as CCP for immediate processing upon arrival at the BC's manufacturing laboratories.

F I G U R E 4 US FDA's CCP donor criteria during the study period

All CCP donors underwent ABO/Rh, U.S. FDA RTTID, and red cell antibody testing. Females with a history of pregnancy were tested for human leukocyte antigen (HLA) antibodies. Units testing positive for HLA antibodies or any of the required RTTID tests were not used for transfusion.

Storage and manufacturing of plasma from whole blood and apheresis were performed following the BC's standard operating procedures. The resulting plasma products were labeled and tagged according to FDA requirements and shipped as liquid or frozen depending on the urgency of the situation. Products were manually tracked and delivered to hospitals as soon as required testing was completed and confirmed acceptable.

From April 2 to 14, 2020, orders were placed by phone or fax. From April 15, 2020, forward, orders were placed through the BC automated blood ordering system software (BloodHub, Phoenix, Arizona). Cost recovery for charges incurred to produce units distributed under the EAP was reimbursed by the Biomedical Advanced Research Development Authority (BARDA) and was issued free of charge to hospitals. Units issued under eIND were charged to hospitals using the cost recovery model.

Rapidly changing information from regulatory and accrediting agencies made it imperative that the BCP team, which consists of executive and senior management in all key areas of operation of the BC, implemented the most current requirements in a controlled and compliant manner. This was accomplished by directing senior quality assurance (QA) staff and medical directors to audit and oversee the new processes. Labeling, licensing, interstate shipment, lookback, and notification information was implemented in accordance with FDA requirements; however, the fluidity of the situation did not allow time for necessary Blood Establishment Computer System changes and controls, resulting in the need for manual workarounds and planned deviations involving standard operating procedures, other documents, and related training.

All communications were coordinated with the marketing team to ensure consistent messaging. Concerted attempts were made to assure ongoing and proactive CCP inventory communications with hospitals and physicians. In addition to regular email communications with hospitals, the BC Chief Medical Officer (CMO), Executive Vice President, and Medical Director gave multiple SARS-CoV-2/COVID-19 updates to the FMA Board of Directors. In addition, the CMO initiated a series of communications with the American Hospital Association (AHA), the American Medical Association (AMA), and America's Blood Centers (ABC) regarding the need for CCP donors. The Chief Executive Officer (CEO) and CMO were also in close contact with the Florida Governor's office and the State Surgeon General, providing frequent updates focused on the critical need for CCP F I G U R E 5 Phase 1 health history questionnaire donors, the status of CCP inventory, and COVID-19 epidemiologic research.

In late-March, 2020, in anticipation of changes in working conditions associated with the pandemic, orders were placed for cleanroom coveralls, shoe coverings, lab coats, surgical masks, protective goggles, and red bio-disposal bags for front line collections and therapeutic apheresis team members. Orders for gloves and cleaning supplies were increased. No staff were furloughed, but staff hours were flexed, and staff redeployed as needed to accommodate rapidly changing needs. All administrative staff were directed to work remotely and Mission (Hazard) Pay incentives were implemented for hourly employees and increased on March 29, 2020. Employees were informed via frequent email updates and the company Intranet which hosted two informational pages; one with all employee-related updates and frequently asked questions, and the second with educational information and communications regarding the BC's CCP processes. Daily meetings of the BCP and ad hoc project teams were also conducted. In addition, by April 15, 2020, the inventory/distribution aspect was automated via blood ordering system software that accepted orders for CCP from the BC's hospital partners. Each order required a patient eIND or EAP number and blood type. CRM automated reporting of the F I G U R E 7 Progressive donor and product losses Total discards due to testing 111 collections throughout the day provided advance notice of incoming components. This allowed for efficient planning of product allocation. It also allowed for real-time updates to the hospitals and clinicians caring for COVID-19 patients. Streamlining the intake process resulted in the elimination of the HHQ on April 28, 2020, in favor of a simpler, fully automated form that could be completed online designed using Click Dimensions software (Click Dimensions, Atlanta, Georgia) ( Figure 6) There was a progressive loss of donors and products throughout the process (Figure 7) . Unique donation discards due to specific test results are listed in Table 2 and were comparable to those seen in the traditional donor population. In comparison to the manual phase 1, CCP production and distribution increased significantly during automated phase 2 of the project, ranging from means of 11 donors collected and 18 products distributed per day in phase 1 to 25 donors collected and 25 units distributed per day in phase 2 (227.3% mean an increase in donors collected and 38.9% mean an increase in products distributed per day). Social distancing measures such as only collecting one donor on a mobile unit resulted in low collections during certain days especially early in the process when only a few mobiles were operational. The backlog of patient orders was cleared, and inventory was able to be built less than 4 weeks after the initiation of the project (Figures 8  and 9 , and Table 3 ).

We herein described the 6-week implementation of a de novo CCP program which was able to identify and recruit qualified donors and track and timely distribute CCP units to patients with critical and life-threatening COVID-19 disease. The CCP initiative described here had two aims: (a) to rapidly increase CCP production capacity to fulfill a critical need and (b) to build an inventory of CCP products to improve product delivery turnaround times. Based on the results of the timeframe described, we considered our goals to have been met. In reflecting on lessons learned throughout the process, the following key areas were identified.

Comprehensive data were lacking regarding the regional and national blood supply, the number of units available in hospitals, and hospital usage patterns. This impaired the ability of the BC to predict the effect of the pandemic on the blood supply. As it impacted a large portion of the nation's BCs simultaneously, it affected the BC's ability to move blood from unimpacted to impacted areas. Additionally, lack of data impaired the BC's ability to predict the effect of cancelation of elective procedures or the regional need for blood products, a capability which would have proven invaluable for integrating CCP production planning into operations.

There were issues with communication at all levels, particularly nationally, highlighting the need for enhancing existing networks and communications pathways and keeping them open. Various parts of the nation were impacted in different ways and times by the pandemic, resulting in disjointed communications between regions and national organizations regarding the prioritization of the need for resources. The FDA and other national and regional organizations compensated for these gaps by always making themselves available. At the regional level, the BC Communication team's proactive approach proved effective in controlling messaging to employees and the public.

CCP donor recruitment challenges were mainly attributable to the BC lack of access to qualified CCP donor lists. This resulted from regulations intended to protect patient privacy but had the unintended consequence of inhibiting the hospitals and health departments from sharing needed information about individuals who had recovered. This resulted in weeks of delay in CCP inventory development. Another donor recruitment lesson learned was related to timing. Initially, the FDA required a 28-day deferral period after a CCP patient became asymptomatic. Since the epidemic was in its early stages in the U.S., many COVID-19 convalescent individuals had only recently recovered from their illness. Therefore, the 28-day wait period significantly limited the size of the eligible donor base and the number of repeat donors.

The lack of licensed tests for SARS-CoV-2 presented challenges to donor recruitment and CCP product characterization. There were a plethora of new serologic and molecular tests on the market for SARS-CoV-2 that had received EUA by the FDA, however, lack of test availability remained an issue throughout the two phases. Trained staff were required to check the FDA website of EUA approved tests to determine if the tests (utilized by donors) qualified. 13 This process was an impediment to rapid donor intake and processing.

Since there were no widely available antibody titer tests to verify CCP product efficacy the FDA recommended additional donor samples were to be collected and stored for future titer testing. The availability of extra serum and plasma sample tubes, per the recommendation of the consultant, proved critical for later titer testing and research.

The need for additional PPE put a strain on the BC at a time when there were national shortages. Severe supply chain shortages of PPE, disinfectants, paper goods, and apheresis kits persisted throughout the project. This created pressure on BC administration to find needed supplies, an effort that was hampered by a lack of prior relationships with vendors. Single source suppliers and just-in-time inventory practices, initially designed to reduce BC expenditures, and exacerbated the situation.

Inconsistent national messaging regarding risk, the safety of blood donation, and the need for PPE resulted in ongoing confusion of donors and staff as to what social distancing measures were appropriate and resulted in the loss of significant numbers of donors and drive cancelations. Proactive communication strategies using social media, emails, and traditional media helped to maintain open lines of dialog with employees and the public, who were reassured by consistent messaging that the BC followed all recommended FDA and CDC guidelines for protective measures and that it was safe to donate.

Clinicians were unfamiliar with the possible utility/efficacy of CCP resulting in hospitals and physicians being inadequately prepared for the rollout of the product. The unproven safety and effectiveness of CCP coupled with a lack of other therapeutic modalities for COVID-19 resulted in uncertainty around availability and use of the product, necessitating ongoing communication between clinicians and BC physicians. Convalescent plasma had been used in previous viral outbreaks for decades, yet only in March 2020, did the FDA authorize the collection and use of CCP by BC and physicians under an eIND or EAP for treatment of COVID-19 disease. The EAP and eIND pathways were unfamiliar to some non-researchbased hospitals and BCs, which found the requirements cumbersome. The lack of coordination and preparation at the BC/hospital level with the national programs (eIND and EAP) and the need for use of manual systems during the early development of the program caused delays and frustration. Physician and public lack of education regarding the challenges faced in implementing a CCP program led to public relations issues for the BC, which was expected to be able to produce CCP on demand, like other blood products.

Another lesson learned was that while a CCP donor may present, there is no guarantee that a successful collection will occur. Even if CCP is obtained, ABO incompatibility might make the unit unsuitable. This was also a point of education for the ordering physicians who recruited family members to provide directed donations. The BC policy was to distribute only ABO compatible plasma. The BC medical directors were available to consult with physicians who may have considered the use of incompatible plasma. Situations occurred in which family members were assured that the unit would be obtainable shortly after the donation only to discover later that the unit was unusable for various quality reasons.

The preexistence of a strong implementation support structure including the PMO, in-house IT/Business Intelligence (BI) unit (a group of computer scientists who mine data and develops algorithms to ensure collections are optimized to match hospital's transfusion needs), and BCP teams at the onset of the pandemic greatly enhanced BC responsiveness to the CCP project challenges and proved to be critical in disaster management. The PMO at the BC consisted of a dedicated, experienced team of professionals, skilled in project management, who were rapidly deployed on the project to develop and revise processes and training in response to frequent changes in FDA requirements. This department played a pivotal role in ensuring the success of the project.

The IT/BI team was instrumental in streamlining and automating the intake and distribution aspects of the process. The BI team tracked and transformed complex data into highly functional dashboards and reports that allowed real-time assessment and strategy development ( Figure 10 ).

The BCP team performed daily horizon scanning on a global level and kept BC Leadership apprised of the progression of the pandemic and any additional threats. They gathered the CCP implementation team together daily for updates to facilitate and maintain communication in an extremely fluid environment.

The SARS-CoV-2 global pandemic has unexpectedly thrust the blood banking community into the international spotlight and challenged it in a manner that was not fully anticipated, causing blood bankers to become acutely aware of the strengths and weaknesses in the system. The public and the government now look to the blood banking community for recommendations to ensure a safe and available blood supply at times when it is needed most urgently. This involves building on the strengths and correcting the deficits and gaps identified in sustaining the blood supply during this global pandemic.

Based on the experiences of this BC from March 24 through May 17, 2020, the following was concluded:

• There is an urgent need for reliable, real-time data on national blood products inventory and usage down to the regional level. • The single supplier, just-in-time inventory model is not suitable for disasters. BCs would benefit from a stockpile of several weeks' worth of critical supplies (eg, PPE and collection kits), and relationships with multiple vendors in diverse locations. • Established federal and state mechanisms are needed to allow public health departments, hospitals, and physicians the discretion to release select elements of protected patient information in the event of a significant disaster. • The federal government should have mechanisms in place for streamlining processes for donor recruitment, testing, and new product development in the event of another pandemic (or disaster) of significance to the nation's blood supply. This would allow BCs to have emergency SOPs, IT pathways, and training in place when needed. • It is likely that there will be future outbreaks of infectious agents that may require treatment with convalescent plasma. Therefore, there should be standing federal protocols in place to allow rapid deployment of this product. • In the event of a pandemic caused by an agent that is transfusion-transmissible, pathogen reduction of the entire blood supply would be required, therefore rapid development and consideration of funding for this capability should be a top priority. • BCs benefit from robust, preexisting, dedicated PMO, IT/BI, and BCP capabilities in the event of a disaster.

The SARS-CoV-2 pandemic represents a unique event that has highlighted the need for planning for the unplannable. BCs' real-time documentation of their collective experiences with managing this pandemic will serve to better inform strategies for future disasters. 

The authors have no conflicts of interest to report.

Data provided in the manuscript may be used by the reader without permission from the author but the author should be referenced.

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 -11

First case of 2019 novel coronavirus in the United States

Cases spike in Wuhan mystery pneumonia cluster

Projecting hospital utilization during the COVID-19 outbreaks in the United States

Effectiveness of convalescent plasma therapy in severe COVID19 patients

Treatment of 5 critically ill patients WithCOVID-19 with convalescent plasma

FDA Investigational COVID-19 Convalescent Plasma Guidance for Industry US Department of HHS FDA. Updated

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan

Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience

This statement was conducted with ethical considerations for the blood donors involved.

Richard R. Gammon https://orcid.org/0000-0002-1175-9579